THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN ACUTE PHASE OF SCHIZOPHRENIA IN TURKEY

Author(s)

Bilge Kanbur, MD, Health Economics Manager1, Oguz Karamustafalioglu, MD, Assoc. Prof. Dr2, Nesrin Dilbaz, MD, Assoc. Prof. Dr3, Solmaz Turkcan, MD, Assoc. Prof. Dr4, Fatih Sarioz, MD, Health Economics Manager1, Fahreddin Tatar, PhD, Health Policy Director11Janssen-Cilag, Istanbul, Turkey; 2 Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 3 Ankara Numune Training and Research Hospital, Ankara, Turkey; 4 Bakirkoy Mental Diseases Training and Research Hospital, Istanbul, Turkey

OBJECTIVES:Schizophrenia is a chronic illness with great economic burden. Paliperidone ER is a new atypical antipsychotic drug in Turkey. The aim of the study is to estimate the cost-effectiveness of paliperidone ER compared to other oral atypicals (risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole) in acute phase of schizophrenia.METHODS:Model: An existing decision analytic model is adapted (based on literature and expert panels). The time horizon is six weeks. The study is performed from the health care payer perspective.Patient group: Patients diagnosed with schizophrenia that have suffered an acute exacerbation.Data sources: The clinical data are acquired from the literature. Resource use data are derived via expert panel. Prices of medications, institutional discount rates and other costs related to the treatment are obtained from Ministry of Health Drug Price List, Price List of Social Security Institution Health Implementation Guideline Appendix 2/D, 8 and 9, respectively.Clinical and economic outcomes: The clinical outcome measure is the number of patients responding. The response rate describes the proportion of patients who benefited from the therapy. This is defined as those achieving decrease of 30% or above to baseline in total PANSS score. Only direct medical costs, i.e. costs of antipsychotics, treatment of side effects, physician visits, hospitalization and laboratory examinations are considered. The results are presented as (ICER) additional cost per additional patient responding.RESULTS:Results are as follows: Total costs: €488, €444, €459, €629, €732, €712; response rates: 0.42, 0.36, 0.41, 0.33, 0.30, 0.32 for paliperidone, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole respectively. ICER is €760/responder for paliperidone. One-way sensitivity analyses prove that results of the study are strong.CONCLUSIONS:In the acute phase of schizophrenia, paliperidone is the dominant therapy in comparison to quetiapine, ziprasidone and aripiprazole. Compared to risperidone and olanzapine, it is the cost-effective therapy option.

Conference/Value in Health Info

2008-11, ISPOR Europe 2008, Athens, Greece

Value in Health, Vol. 11, No. 6 (November 2008)

Code

PMH16

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Mental Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×